Related Experiment Video

Updated: Mar 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

[Early clinical trials in paediatric oncology in Spain: a nationwide perspective]

Francisco Bautista1, Soledad Gallego2, Adela Cañete3

  • 1Unidad de Investigación Clínica CNIO-HNJ, Servicio de Hematología, Oncología y Trasplante de Progenitores Hematopoyéticos, Hospital Infantil Universitario Niño Jesús, Madrid, España.

Anales De Pediatria (Barcelona, Spain : 2003)
|March 11, 2017
PubMed
Abstract

Insights

Early phase clinical trials for paediatric cancers in Spain have increased since 2010, offering new treatment opportunities. This includes novel targeted therapies and immunotherapies, improving outcomes for children with malignant haemopathies and solid tumours.

Area of Science:

  • Paediatric Oncology
  • Clinical Trial Research
  • Cancer Therapeutics

Background:

  • Cancer remains a leading cause of death in children and adolescents, necessitating novel therapeutic strategies.
  • Translating adult cancer drug development advancements to paediatric settings is crucial.
  • Early-phase clinical trials are vital for introducing new anti-cancer drugs in children.

Purpose of the Study:

  • To report on the activity and trends in early-phase (I-II) paediatric oncology clinical trials in Spain between 2005 and 2015.
  • To assess the landscape of paediatric cancer research and treatment development in Spain.

Main Methods:

  • A survey was conducted among members of the Spanish Society of Paediatric Haematology Oncology (SEHOP).
  • Data collected focused on early clinical trials initiated in Spain from 2005 to 2015.

Main Results:

  • Thirty early-phase clinical trials were identified, with 70% focusing on solid tumours and 30% on malignant haemopathies.
  • A total of 212 patients were enrolled, with 53% of trials being industry-sponsored.
  • Since 2010, increased trial activity and participation in international consortia like ITCC have been observed, introducing molecularly targeted agents.

Conclusions:

  • Paediatric oncology clinical trial activity in Spain has significantly increased.
  • Collaborative academic trials are essential for advancing and optimizing paediatric cancer therapies.
  • Spanish investigators are contributing to the development and benefits of novel anti-cancer agents for children.
Keywords:
Desarrollo de nuevos fármacosDrug developmentEarly phase clinical trialsEnsayos clínicos precocesMedicina personalizadaOncología y hematología pediátricaPaediatric haematology and oncologyPersonalised medicine

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

3.0K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

788

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304